1502
ONKOLOGIE3418043010760120167227269329388409453
/8408043010731
Onkologie.9168043010761110147195214263313331375390
2023;17(1):51-561326804301074487128172186223260280320338352397436459502545
/19168043010731
www.onkologiecs.cz48658043010765133201214262311348396415464514532576617652669709748
561838026012657115
PŘEHLEDOVÉ341207012660124182256312369444520587645
ČLÁNKY1008207012660115187259327395
Mechanismy34136501065284118160199241258290344380
rezistence73736501063365100118150183215256291323
na107636501063979
imunoterapii117036501061669110151192222255290332367384401
melanomu158736501065284115157198239293333
4.3405530853651
Robert4085540833574113149170195
C,6205540834053
Thomas6905540833271110168200227
L,9345540833145
Bondarenko9965540833574112151184205239277307345
I,13585540831427
et14025540833456
al.1475554083324861
Ipilimumab15535540831453698499157194252285324
plus1894554083395492118
Dacarbazine3406540834781115149172214248280297336373
for740654083195882
Previously848654083365894128146185226253270304
Untreated11786540834585108131167201224259301
Metastatic15056540835794117152180205239263279313
Melanoma.184565408356931101443407540833878137171184
N54675408345
Engl6137540833372112128
J76275408324
Med.8087540835591132146
2011;364(26):2517-2526.9757540833570102131140176211249269304338357369406441473504523555590625659673
doi:10.1056/1669754083397894107138170183215247282318343
NEJMoa1104621.3408540834578105159198231261288320356392425457466
5.3409530853650
Larkin403954083316485116132170
J,5869540832436
Chiarion-Sileni634954083407893124145161199237259290305320355392407
V,10549540833644
Gonzalez11119540834482121150183198233262
R,13869540833549
et14489540833456
al.1517954083314759
Five-year1589954083324779114136168202234255
survival18579540832663841181343401054083326580
with4341054083516789127
combined57610540833168126165181219254293
nivolumab8841054083375285122138176234266305
and120410540833170109
ipilimumab1327105408315546985100157195253285324
in166610540831452
advanced173310540833171103136174206240280
melanoma.34011540835791106137175212269301314
N666115408344
Engl72211540833369108122
J857115408324
Med.89311540835388127139
2019;381(16):1535-1546.10441154083346799128140175208239254285315333344373403435467489519548583618631
doi:10.1056/16871154083377590101131161173203234267301325
NEJMoa1910836.34012540834578105159198231261291323354390424458471
6.34013530853651
Robert40413540833573113148169193
C,61013540834053
Long67613540833168106145
G834135408343
V.,8901354083364557
Brady9601354083355689128160
B,113313540833547
et119313540833456
al.12621354083324760
Nivolumab13341354083456092130145183240272311
in165813540831552
previously17231354083396094126142179217243258290
untreated3401454083377597118152184205239279
melanoma63214540835792107139177216274306
without9511454083516688127165203225
BRAF118914540833672114147
mutation.134914540835795118150172187225263277
N1639145408344
Engl169614540833370109125
J1834145408324
Med.187114540835489129142
2015;372(4):320-330.34015540833468100130141176208242260293310322357390424448480513547560
doi:10.1056/NEJMoa1412082.9151554083387792104134165178209240274309334379413439494533566595626657687721756790802
7.34016530853645
Schachter40416540833265103135167205227261282
J,70516540832436
Ribas7611654083355190123149
A,93016540834155
Long100416540833169107146
GV,11701654083438089
et127816540833457
al.13541654083324760
Pembrolizumab143416540833568126165187224240255284322380413452
versus190516540833266873401754083266390
ipilimumab446175408315547085100158195253285325
for7871754083195678
advanced88217540833170103136174206240279
melanoma:117817540835793108140178217275307320
final15141754083173472104120
overall165017540833870104125158173189
survival185517540832664851201353401854083326580
results4401854083215582119134157184
of64418540833857
a721185408332
multicentre,77318540835795110133148180213252273295329341
randomised,11341854083205391130169227242268303343355
open-label150918540833877113151173190222261297312
phase184118540833977110136171
3340195408334
study3951954083264987126158
(KEYNOTE-006).5741954083185388125171219251285307344380416434445
Lancet.103919540833265103136169192205
2017;390(10105):1853-1862.126519540833468100129139174207243263295326358389424442454484515549582604635666701735747
doi:10.1016/S0140-6736(17)31601-X.3402054083387692104134165178208240272303328361396427458494518555588623657676708737757790821852887919938974988
8.34021530853653
Hodi41421540834583124139
FS,5742154083336578
Chiarion-Sileni6732154083407994127148164203242264296311327362401416
V,111021540833645
Gonzalez117621540834484123153187202238268
R,146521540833550
et153621540833457
al.16132154083334861
Nivolumab16952154083456194132148187245278318
plus3402254083395592118
ipilimumab472225408315546985100157195253285324
or81022540833759
nivolumab8822254083385386123139177234267306
alone12022254083314785123158
versus13742254083326687115152178
ipilimumab156622540831453698499157195252285324
alone1904225408331478534023540833873
in43023540831553
advanced50023540833271104137175207240280
melanoma79823540835792108140178216274307
(CheckMate11222354083195896131164194250283305338
067):147823540833470103122134
4-year16302354083345789123155176
outcomes1824235408337759812816534024540835792119
of47524540833857
a548245408332
multicentre,59624540835795110133148180214252273295329341
randomised,9532454083215492131169227242268303343356
phase132524540833877109136171
31512245408334
trial.1562245408322435991106119
Lancet169724540833265103135169191
Oncol.190424540834786340255408331678295
2018;19(11):1480-1492.4472554083346798129140170199218249276290302331361396431454484515547580592
doi:10.1016/S1470-2045(18)30700-9.10512554083387590102131161174204234266296321353383413445477500531564599632649680710728760794826858893917951961
9.34026530853751
Ayers41226540834272108130158
M,59126540835670
Lunceford68226540833270109142177196235257297
J,100026540832537
Nebozhyn105826540834682122162191231262302
M,138126540835670
et147226540833558
al.15512654083334962
IFN-γ-related16342654083154995118150174196231248281303338378
mRNA34027540835793139180
profile5372754083386097115132147182
predicts7352754083396094134149181205233
clinical9842754083324762100115147180195
response11952754083215582121160198224259
to147127540832258
PD-1154627540833580104135
blockade.16972754083395493125155189228263275
J1988275408325
Clin3402854083405570108
Invest.4632854083155384119145169182
2017;127(8):2930-2940.66028540833469100130139170199232249282301312348382414449473504538574610622
doi:10.1172/JCI91190.12982854083387691103133165177208236265299326347388403437469496527562575
10.3402953085366983
Hugo43629540834481119157
W,60629540835766
Zaretsky6852954083377090123145172201234
JM,9322954083247891
Sun103629540833269106
L,115529540833144
et121229540833455
al.12802954083324658
Genomic135129540834478116153211225257
and162029540833269108
Transcriptomic1740295408333498211914517619721225034030540832157113127158
Features5093054083326595116152172205230
of75030540833755
Response8163054083356894131169206231264
to109130540832257
Anti-PD-111593054083417798112133168212234264
Therapy143330540833370104124156193223
in166730540831551
Metastatic172930540835487109140165187219239253284
Melanoma.34031540835487101132168204261291303
Cell.654315408339718599111
2016;165(1):35-44.7753154083346697126137166195227243274287297331362383417453464
doi:10.1016/j.cell.2016.02.065.1250315408337738798126156168197227257286310325336367399413427438472505535565577610641652686720752763
11.3403253085366575
Vilain426325408336516495109145
RE,5813254083366880
Menzies67132540835488125152167200225
AM,90732540834095107
Wilmott10243254083577286142179199222
JS,12563254083245566
et133232540833455
al.13973254083324658
Dynamic146532540834576114145201215245
changes17203254083326899136173207232
in196232540831551
PD-L134033540833578100131159
expression50933540833463101121153178203216252289
and80733540833268105
immune92233540831470126161198231
infiltrates116233540831551678497118137168188220245
early1417335408334648397127
during15543354083387393107143180
treatment17443354083214173103123179212248268
predict3403454083395991130143174197
response5533454083215479117154191216250
to81934540832258
PD-189334540833579101131
blockade10403454083395490122150182220254
in131034540831551
Melanoma.137834540835588102133170207264295307
Clin17013454083405467104
Cancer182234540834071108138171191
Res.3403554083356994106
2017;23(17):5024-5033.4563554083346797125133167200216246274292303337369400431452485517549580591
doi:10.1158/1078-0432.CCR-16-0698.1057355408338758999128158169198224252285309340370401433454490525556587598636673707727756786808843878910943955
12.3403653085366884
Snyder43836540833270101139174195
A,64736540834155
Makarov71636540835587118151172209241
V,97136540833645
Merghoub103036540835489111149187225263302
T,134636540833342
et140236540833456
al.14723654083324760
Genetic154636540834479117152175190222
basis17823654083397298113139
for19353654083185678
clinical340375408331476199114146179195
response5533754083205581120159198224259
to83037540832259
CTLA-490737540834075108152173210
blockade11353754083385492125155189228263
in141637540831452
melanoma.148637540835893108141179217275308321
N1825375408345
Engl188837540833270109124
J340385408324
Med.37838540835489129142
2014;371(23):2189-2199.53338540833569100131143178210243258292327344356391422453488511542574604639650
doi:10.1056/NEJMoa1406498.11973854083387691103133165177208239273308333379412439493532565595626662697734767802815
13.3403953085366883
Jiang4433954083243971109148
T,61139540833241
Shi6723954083327085
T,77639540833342
Zhang83739540833876108146185
H,104239540834457
et111839540833456
al.11943954083314760
Tumor127339540833366124162184
neoantigens:147639540833873111144182204219258293331357370
From18653954083335290148
basic34040540834074102118151
research5144054083215785122155177210250
to78640540832261
clinical8704054083324864104120153188204
applications.109740540833273114131147181215238254294334362376
J1496405408325
Hematol154340540834682143176199238255
Oncol.182140540834888122160177191
2019;12(1).34041540833468100130143173203220252266277
doi:10.1186/s13045-019-0787-5.6334154083387691104133165177208236267302327352382412446482515537574606636660697730763796815849861
14.3404253085366984
Jäger4374254083245695130151
E,60142540833245
Ringhoffer6594254083365189128166204223242277298
M,97042540835467
Altmannsberger10504254083415679137169207245271310345366404439460
M,152342540835468
et160442540833456
al.16734254083314759
Immunoselection1745425408315731301682062443404354083266177112144168184222260
in61443540831452
vivo:6804354083314780117130
Independent8234354083155392127166202240279314352373
loss12104354083155380106
of133043540833756
MHC140043540835499140
class15544354083314678105131
I1699435408315
and172743540833270109
melanocyte18504354083579210814034044540833876108142167201
differentiation554445408338537392126147181219241256288310325363402
antigen9694454083327091107145180218
expression120044540833466105127161188215229267306
in151944540831553
metastatic158544540835792114147174197230251267299
melanoma.1897445408357923404554083154887126185219232
Int5944554083155375
J691455408324
Cancer.73645540834174113146181202213
1997;71(2):142-147.97045540833566102136146179213228263281294324356389410442474506513
doi:10.1002/(SICI)-15044554083397894106137169182213246283316344361394409450466485508
1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0.34046540833466101134152189222254284301333363399431465501531563581612645653689727759790822835848890905951975991101710571093113311631176121112241263130913211356137714141426
15.3404753085377187
McGranahan45047540835690137160194234268308342381
N,85547540834660
Furness9384754083337194134171199227
AJS,118847540834371105118
Rosenthal133047540833676104141181204243277294
R,164747540833752
et172247540833559
al.18044754083334963
Clonal189047540834258983404854083397289
neoantigens45248540833975116150190213229270306346374
elicit8494854083355268101117141
T1013485408334
cell10704854083326884100
immunoreactivity119448540831575135174214254277313346380405421456472496531
and174948540833272113
sensitivity188548540832764104340495408327436783117134158193
to55749540832361
immune64249540831576136175215252
check-point91849540833272108143174196238278295335357
blockade.13004954083395696131162197238275288
Science16124954083346884120160194229
(80-).18654954083195592117136148
2016;351(6280):1463-1469.34050540833468100131143178211243258291324358393412424453484520554576607638674708719
doi:10.1126/science.aaf1490.10745054083387792104134165178209236266300325349382397431469502535547581614633665696729765778
16.3405153085366985
Gros43851540834465103129
A,58051540834155
Parkhurst6485154083356788119158196217244267
MR,92851540835591105
Tran10465154083335083121
E,118051540833245
et123851540833457
al.13085154083324760
Prospective13815154083355693120158194227251266299333
identification172751540831553881261481631811982302633405254083223775113
of47352540833857
neoantigen-specific55052540833772111144182204219258293331353380419455487502520537569
lymphocytes113952540831547105144183221254287312346373
in153252540831452
the16045254083226095
peripheral17195254083397495111150189224245278293
blood3405354083395593131171
of53153540833757
melanoma60853540835792108140178216275307
patients.9355354083397293109143182203231244
Nat12005354083447798
Med.131953540835489129142
2016;22(4):433-438.148153540833468100131143178213230263281293327360393414451484518532
doi:10.1038/nm.4051.3405454083387692104134165178208240273307333369427440475510545576585
17.3405553085366876
Nowicki43355540834583134150182212228
TS,6785554083326679
Hu-Lieskovan77355540834482104137153187214244282314346384
S,117455540833245
Ribas12365554083355190123149
A.140255540834155
Mechanisms147455540835489122160192230246272329356
of184655540833757
Resistance191955540833671340565408326416790123161193227
to58556540832259
PD-166256540833580104134
and81556540833169108
PD-L194256540833580103137166
Blockade.11265654083365290122152186225260272
Cancer141656540834073111143177198
J1632565408324
(United167456540831963101116138172212
States).19045654083325386340575408322558299110
2018;24(1):47-53.46657540833468100131143178210229261275287322354372406439452
doi:10.1097/PPO.0000000000000303.933575408338769210413416517820824027530832836439944745849453056660263867471074678381985589192796099510281040
18.3405853085366985
Long43758540833168106145
G595585408343
V,65158540833544
Larkin7085854083316485115131169
J,89058540832435
Ascierto93858540834168100115150171195232
PA,11825854083357286
et128158540833456
al.13495854083324760
melanoma142258540835791107139176214272304
and173958540833269108
other18605854083375896131152
skin3405954083265774112
tumours47359540832260119158197218246
1112PD7405954083356391121157202
PD-L196359540833681106139170
expression115359540833567107129164191218233272311
as148559540833259
a1565595408332
biomarker16185954083395594153186207238273295
for19345954083185678
nivolumab3406054083385386124140178236268308
(NIVO)6696054083186479116164182
plus8716054083395593120
ipilimumab1011605408315547086101159197255288327
(IPI)1359605408318347084103
and148360540833270109
NIVO16136054083456198145
alone17796054083324786124160
in195960540831553
advanced34061540833271104136174207240280
melanoma64061540835792108140178216274307
(MEL):96761540831872105137156168
A1154615408341
pooled121561540833978116132167207
analysis.144261540833169102117149176191217230
Ann169261540834179117
Oncol.182961540834786118155171184
2016;27:379-400.34062540833468100131143178211221257289322346382418454467
doi:10.1093/annonc/mdw379.7.8226254083387792104134165178209240275308332363401439477515548575631670722754786819830864870
19.3406353085366778
Carlino4286354083407190104117153190
M,62863540835465
Ribas7036354083354986117142
A,85563540834153
Gonzalez91863540834380117144176189222250
R,117863540833547
et123563540833454
al.12996354083324557
Abstract136563540834178103125144176206228
CT004:160363540834074106140174185
KEYNOTE-006:1798635408334671021461923406454083336585121156190201
PD-L155664540833578101132161
expression73164540833464102123155181206219256293
and103864540833269106
efficacy1159645408334516886117148179211
in138564540831451
patients14506454083397091105138175195221
(Pts)16856454083195375102117
treated18176454083214174104125157195
with3406554083506484121
pembrolizumab47065540833972128165185220234247275311367397434
(pembro)9146554083185689145182202237253
vs117765540833156
ipilimumab124365540831451657992147183239269306
(IPI)155965540831832657895
for16646554083185373
advanced17476554083316899130166196228266
melanoma.34066540835689102132168204259289300
In:6496654083155061
American71966540834095128147160190220256
Association9846654083406690126156169199219232267303
for12966654083185473
Cancer137866540833970105135166186
Research15736654083346792124154173201237
(AACR);18196654083185797134167184193
2016:CT004-CT004.3406754083346797127138178212245279314336377412444479514525
doi:10.1158/1538-7445.am2016-ct004.878675408338748899128158169198224253286310341370402435456486515550582592625681714747777807829861884918953988999
20.3406853085367287
Larkin4486854083316586117134172
J,64068540832537
Chiarion-Sileni6976854083407894126147163201240262294309324359397412
V,113068540833645
Gonzalez119568540834483122151185200235265
R,148168540833549
et155168540833456
al.16286854083324760
Combined170968540834077136175191229264304
Nivolumab3406954083456093131147185244276316
and67769540833270110
Ipilimumab807695408315557186101159197256289328
or115669540833759
Monotherapy123669540835594133171193232267289322362393
in165069540831553
Untreated172469540834482104126160192214249288
Melanoma.34070540835693109143182222283317331
N693705408346
Engl76170540833373113130
J912705408325
Med.95970540835693134148
2015;373(1):23-34.112970540833571104135147183217253272305320333370406429463500513
doi:10.1056/16647054083397995108139172186218251286322348
NEJMoa1504030.34071540834578105159198231261291325361397430465477
21.3407253085366879
Parsa4337254083356685111143
AT,5897254083416976
Waldron67972540835787101139159194231
JS,9247254083245566
Panner100372540833666103139173193
A,120972540834154
et127672540833455
al.13457254083324657
Loss14167254083316792117
of154772540833755
tumor161672540832158114151171
suppressor180172540832662991381581913407354083265086106
PTEN4557354083356799141
function6067354083185490120142156192228
increases8437354083155080100132161186219244
B7-H110967354083356683126156
expression126173540833463100120152177201214250286
and155773540833167104
immunoresistance1670735408315701251611972332522843093223407454083264778115145177
in52774540831450
glioma.5877454083385265101157188200
Nat7967454083457595
Med.90174540835488125137
2007;13(1):84-88.104874540833466100131139167196212242255265298332354388421433
doi:10.1038/nm1517.1491745408338748898126156167196226257290313348404432460489517521
22.3407553085367288
Peng44375540833569107146
W,60375540835867
Qing68575540834763100139
Chen83975540834078113151
J,100475540832436
Liu10557554083314784
C,115475540834053
et122175540833456
al.12927554083324760
Loss13667554083326996122
of150375540833756
PTEN157475540833569103148
promotes17367554083396098156194216250277
resistance340765408321558296122146178216249282
to64076540832259
T716765408333
cell-mediated767765408331658095118176211251266298320353393
immunotherapy117876540831472130168206244266304339360393432464
Analysis165976540834179112127159186201227
and190476540833169109
interpretation2140554083155374108129169190224247280301317355393
of25515540833756
data2625554083387092125
(statistical2768554083184467100122137163186202233266282
analysis30685540833169102117149176191217
and33035540833169108
bioinformatic3429554083395492108146165202224282315336352384
analysis):21406540833169100115146173187213229241
HHS23936540834487119
Public25246540833572110125140171
Access.27076540834172102135161187200
Cancer29206540833971108140173194
Discov.3126654083456085117153184194
2016;6(2):202-216.3332654083346798129141176194227245256291324356376406437468481
doi:10.1158/2159-8290.CD-15-0283.2140754083387692104134165178208236266300326360392422454478514547581617630669715739769799822859892925959972
23.2140853085357185
Ni22378540834458
K,23078540833448
O’Neill23678540834659103137152166180
H.25598540834356
The26278540833270104
role2743854083205671105
of28608540833655
dendritic29278540833771108146166181203217248
cells318785408330637892117
in33168540831551
T337985408332
cell342385408331637892
activation.3527854083316386100132164185199236273286
Immunol21409540831571128165202240255
Cell2408954083397287102
Biol.2522954083355087103115
1997;75(3):223-230.2650954083336398130139171203221254270282316350384406436470504516
doi:10.1038/icb.1997.35.3178954083387590102131162174204235268301326342373411423454483518550556591623634
24.21401053085367187
Wu224810540835895
W,236410540835767
Wang245210540835889128167
W,264010540835767
Wang272810540835889128167
Y,291610540833544
et298010540833457
al.30581054083324760
IL-37b3139105408315476295127166
suppresses332610540832664103143165199226253289316
T3662105408333
cell3716105408331658196
priming21401154083396076134149187226
by238211540833970
modulating246811540835896136173188221242258296335
dendritic281911540833873111150171187209225257
cell3092115408331658095
maturation320411540835790111149170203225240278317
and353711540833270109
cytokine3663115408331648912621401254083304684119
production22771254083396097137175207231246284323
via26181254083314779
dampening271512540833871128168203241256294333
ERK/NF-κB/S6K306612540833368104133179212233267303328361396431
signalings.35151254083274180118150166181219258284297
Acta214013540834275100134
Biochim22951354083375392126165181241
Biophys25571354083375392133173205233
Sin28111354083344988
(Shanghai).29211354083195291125164204244277293313325
2015;47(8):597-603.326713540833570103135146182215233267286299336369403423461498532545
doi:10.1093/abbs/gmv058.21401454083387692104134165178208240275308332362402441468494529587619655689723737
25.21401553085357084
Lindenberg22341554083314581119152188226260280316
JJ,25611554083244657
van26291554083316298
de273815540833871
Ven282015540833566102
R,293315540833548
Lougheed299115540833167103141177210244282
SM,32841554083328496
et339115540833354
al.34561554083314557
Functional352415540833266103133156170206243274288
characterization214016540833168100120153184207240261276304337358372409447
of259916540833755
a2666165408332
STAT3-dependent270916540833366103131166187227261299334371410444481502
dendritic322216540833873110148169183205220251
cell-derived3484165408332657994115155189209224256290328
CD14214017540834085115146
+2302175408342
cell2360175408332657994
population247017540833977116153168200221235272310
arising2797175408331526792106143182
upon299517540833776114152
IL-10-driven3163175408315466090121144184205219251285322
maturation350217540835789110147167200221235273310
.2140185408312
Oncoimmunology.216618540834785117153167224282319356393409446485516526
2013;2(4):e23837.27061854083346798127138172189221238249283317351384418449455
doi:10.4161/onci.23837.31741854083397691102131162174208237268297318352390422436448484518551585616622
26.21401953085367187
Emeagi224419540833390125157196211
PU,24721954083357889
Maenhout257719540835587122160199237275297
S,289119540833245
Dang295219540834678116155
N,312319540834558
et319719540833456
al.32701954083314760
Downregulation334619540834584135174195229268306321353375391428467
of214020540833756
Stat322092054083325385107142
in236420540831452
melanoma:242820540835792107139177215273305317
Reprogramming275720540833570109130167206227260317374389427465
the32352054083225994
immune334220540831471129166204238
microenvironment35932054083577210412516119721402154083376883103140178234269306327
as247921540833157
an254921540833168
anticancer26292154083326990105136168205237270290
therapeutic29322154083215893113146184219256278292324
strategy.32682154083264869101123156194226235
Gene351521540834478116150
Ther.367721540833271105126135
2013;20(11):1085-1092.214022540833468100130141176210230262289304316345377412446468499531566599611
doi:10.1038/gt.2013.35.27672254083387692104133165177208240273307332368391404440474506536548584617629
27.21402353085357078
Hong223123540834481119157
M,240023540835467
Puaux248023540833471102139170
AL,26622354083417285
Huang275923540834481113150188
C,296023540833951
et302423540833355
al.30912354083324759
Chemotherapy316323540833976110167205226264298319351389420
induces35952354083155290127159192218
intratumoral2140245408314517292124145182238275296327342
expression249424540833364102122155181207221258295
of280124540833655
chemokines286724540833168101158195224240277310336
in321524540831451
cutaneous32782454083306789120157191228265290
melanoma,358024540835690105136173210214025540835789102
favoring22542554083185183120141156194233
T-cell24992554083335184117133147
infiltration2659255408315526986101123144177198213251289
and296025540833270108
tumor308125540832159116154175
control.326925540833168106127148185201213
Cancer349525540833972110141175196
Res.37032554083357096110
2011;71(22):6997-7009.214026540833468100128136169201216250285303315350384419452471502535571607618
doi:10.1158/0008-5472.CAN-11-1466.277326540833876921041331651782082362663003253593954314674905245595916256386777207657888198468658969279639991012
28.21402753085377592
Harlin225427540834579101118134174
H,244927540834660
Meng253127540835692132173
Y,272527540833746
Peterson27932754083367194129152180220260
AC,30752754083428397
et319427540833558
al.32742754083334963
Chemokine335927540834180117177217249266306342
expression37232754083356821402854083406398127155170210250
in241428540831555
melanoma249328540835996112146186226287321
metastases283728540835996120154182207241269306334
associated31952854083326088128163179212235271312
with35312854083526992132
CD8368728540834189125
+2140295408343
T-CeII22082954083345398134151167
recruitment.24002954083215792114154171195255292332355369
Cancer279529540834175115149184207
Res.302729540833773102117
2009;69(7):3077-3085.316929540833571109146160197233253290310323360397431467487521558595631644
doi:10.1158/0008-5472.CAN-08-2281.2140305408338769210413416517820823626630032635939543246749052455959162563867772076578882586188391494998310151024
29.21403153085367285
Yue224431540833570105
C,236831540834053
Shen244031540833270105143
S,260231540833245
Deng266631540834581119158
J,284331540832436
et289831540833456
al.29733154083324760
STAT3305231540833267104133168
in323931540831553
CD8+331131540833985120163
T3492315408333
cells3544315408331658095121
inhibits3684315408315539110621403254083395477105
their22653254083226095110132
tumor241732540832260118156178
accumulation26153254083326596133191229245277299314352391
by302632540833970
downregulating311732540833876127166187222261299314347368384422461
CXCR3/359832540834080119155190215
CXCL10214033540834184125159191225
axis.23993354083336784113128
Cancer256233540834176117151187211
Immunol280733540831576137177218259277
Res.311833540833774103119
2015;3(8):864-870.327133540833572106138151188209245265278316354393418456492527541
doi:10.1158/2326-6066.CIR-15-0014.21403454083387692104134165178208236266300326360395428461485522558593629642682697733755785815838875911943974986
30.21403553085367288
Kučera224835540833572104138159192
J,246135540832436
Strnadová25173554083335476114147186224256289
K,282735540833549
Dvořánková289735540834579116138171209239277309342
B,325935540833648
et332835540833456
al.34053554083324760
Serum34853554083336889128186
proteomic3691355408339609821403654083225694153168200
analysis236136540833170102117149176191217
of259936540833757
melanoma267636540835893108141179217276308
patients30053654083387193109143182203231
with32573654083506688127
immunohistochemical340436540831573131168207245284299325348385214037540833169104162177209242257
profiling24163754083386097115132147162200239
of267337540833857
primary27483754083396076134166187221
melanomas298837540835792108140178216274307333
and334037540833169108
cultured34673754083316984107144166200239
cells:3725375408331642140385408315305668
Pilot22243854083354965103125
study.23643854083264987126158168
Oncol254838540834785117154170
Rep.273338540833671110123
2019;42(5):1793-1804.287138540833468100130143178210228261279291321351384417439469500536572585
doi:10.3892/34713854083387692104133165177213247282315341
or.2019.7319.21403954083375969105139171201212246281311342353
31.21404053085367083
Bouzin223840540833574113143160198
C,245140540834054
Brouet25204054083355795134170193
A,272840540834155
De279940540834581
Vriese28954054083365773108136172
J,308240540832436
et313440540833356
al320640540833147
O.326840540834760
Effects33434054083325271106140164193
of355140540833757
Vascular3623405408336689512816621404154083154870
Endothelial223241540833271111150173212248264280312329
Growth258341540834366104156181220
Factor28254154083336396121159181
on302841540833777
the31264154083226197
Lymphocyte-Endothelium32454154083316112016020023927230633236739142646450454321404254083226096112127165224
Interactions:23784254083155375110131165198222238277316342355
Identification27484254083145489128150166184201234267289305344383
of314542540833757
Caveolin-1321642540834073105140179196211250273304
and353442540833271110
Nitric36584254083456184106122154
Oxide21404354083477995134170
as232443540833259
Control239743540834077116139161198215
Points26264354083357288127149177
of281743540833757
Endothelial288943540833270110149171210245261277309325
Cell32294354083397490106
Anergy.334943540834179115137175208219
J3582435408324
Immunol.36204354083157313117021404454083377692105
2007;178(3):1505-1511.225944540833468105137148178208241261294312324354384419453475507537568596606
doi:10.4049/jimmunol.178.3.1505.28794454083377692104134166179213249286319343359375433490528566605621634665695729743778791822852887921933
32.21404553085377390
Huang225245540834585119158199
H,247345540834559
Langenkamp255445540833368107148184224256291351392
E,296845540833347
Georganaki303845540834582122145184218258292323341
M,340145540835670
et349345540833559
al.35744554083334963
VEGF365945540833772118153
suppresses214046540832662101139160194220246280306
T-lymphocyte2458465408332506697155193231268300333357390
infiltration2860465408315526986100122143175196211248286
in315846540831552
the32224654083215993
tumor332746540832259115153174
microenvironment35134654083577110312316019523226327821404754083205794150185222242
through23944754083225979115153191228
inhibition26344754083145188102140155177192229266
of291247540833755
NF-κB-induced29794754083447697129165187202239277314345378416
endothelial340747540833370108146167204238253267298313
activation.37324754083316321404854083213669101123138175213226
FASEB237948540833269103135170
J.256148540832437
2015;29(1):227-238.26104854083346899129139174208226258272283318353385403434468502515
doi:10.1096/fj.14-250985.31384854083387691103132163175206237272307331349365377408438461492526560595629663674
33.21404953085367288
Chen224949540834079115154
PL,24244954083356781
Roh252649540833675115
W,266249540835868
Reuben275149540833672110150187225
A,299849540834156
et307549540833457
al.31534954083324861
Analysis323549540834281114130162190205232
of348849540833858
immune356749540831573132171210245
signatures21405054083264180118150172210231265292
in244750540831552
longitudinal25155054083145391130145168206245260298330345
tumor287550540832260118156178
samples306850540832659117156172207234
yields3317505408331468197136162
insight3494505408315527994132170192
into37015054083155374111
biomarkers21405154083385491149181201232265286313
of246551540833756
response25345154083205480119157195221256
and280251540833269108
mechanisms292251540835792124161193231246271328354
of328951540833756
resistance3357515408321548195121144176214245278
to364851540832158
immune371851540831572214052540835693129163
check-point231552540833167101133162181220257272309329
blockade.26565254083385390122151183221255266
Cancer293452540833971107138171191
Discov.31375254083445984115151182191
2016;6(8):827-837.33405254083346697127139173192224241252286319350368403436467472
doi:10.1158/2159-8290.CD-15-1545.21405354083387692104134165178208236266300326360392422454478514547581617630669715739769799822852882918950962
34.21405453085367388
Ott22465454083477195
PA,23585454083357287
Stephen24625454083325387126165200238
Hodi271754540834482122137
F,287154540833238
Buchbinder292654540833674106144183199236275310332
EI.32755454083324760
Inhibition33535454083145290105144160183198236274
of364454540833857
immune371854540831572214055540835693130164
check-points231655540833168102133163182221259274311331358
and268655540833168106
vascular28045554083326489121157172203224
endothelial304055540833370108145166204238253267298313
growth33655554083375794144167205
factor35815554083195182106141162
as375555540833257
combination214056540833167125164179216248269284322360
therapy25125654083225994115147186216
for27415654083185576
metastatic283056540835791113145172194227248263294
melanoma:313756540835791107138176214271303315
An346456540834179
overview355556540833769102123157173207257
of214057540833755
rationale,2207575408321537488125163194209243254
preclinical24735754083385992124139153190204235267282
evidence,27675754083346580118152189220253264
and304357540833269107
initial3162575408314516687102133148
clinical3322575408331456096111142174189
data.35235754083376990121134
Front36675754083325187125145
Oncol.214058540834786118155171184
2015;5(SEP).233958540833468100130141176193225257293310321
doi:10.3389/fonc.2015.00202.26765854083387691104133165177213246280315338357395433465479515549581611623658694727761794806
35.21405953085367186
Restifo22465954083357097120136155193
NP,24595954083458085
Smyth256459540833390121146184
MJ,27685954083558193
Snyder288159540833370101139174196
A.309759540834156
Acquired317359540834172110148163184218258
resistance3451595408321558296123146178217249282
to375459540832158
immunotherapy214060540831575135174214254277317353376410451484
and264660540833372113
future27826054083185983122144180
challenges.298460540833372106122138175214255292320334
Nat334160540834679102
Rev346660540833673106
Cancer.359560540834175115148184206217
2016;16(2):121-126.214061540833468100131143174205224258276287317347379397428458492505
doi:10.1038/nrc.2016.2.26606154083387692104134165178209240273308333369390422435471505537568581617630
36.21406253085367288
Restifo22456254083357097120136155193
NP,24546254083458185
Marincola255662540835587108124162194231247279
FM,28526254083328599
Kawakami296862540833468119152182215273288
Y,327362540833544
et333362540833457
al.34066254083324860
Loss34836254083326996122
of362262540833757
functional3695625408319579521406354083315571109147179195
beta2-microglobulin23496354083387496129163184242258289311348388403441481519534549587
in295063540831452
metastatic301663540835793115148174197230252267299
melanomas332963540835792108140178216275307334
from36776354083184077136
five21406454083173467101
patients22626454083397294109144182204232
receiving25156454083205588122137170185224263
immunotherapy.279864540831573131169207246268306342363396436467477
J3296645408324
Natl33416454083457799115
Cancer347664540834073112144178199
Inst.36966454083155380103116
1996;88(2):100-108.214065540833464100135147183218237271289301331362398422453484520533
doi:10.1093/jnci/88.2.100.26886554083397792104134165178209240275308332349387419434460494529543579591622653689702
37.21406653085367079
Del22326654083458196
Campo234166540834073130170208
AB,25626654083417790
Kyte26656654083346488122
JA,28006654083246478
Carretero28916654083407394116150172205227264
J,316866540832436
et321766540833456
al.32866654083324760
Immune335966540831572130168206241
escape36136654083346092125164200
of214067540833757
cancer221167540833264102135168189
cells2415675408331658196122
with25526754083506688126
beta2-microglobulin26936754083397497129164184243258290311349388403441481519535550587
loss32956754083155380106
over341667540833869104125
the35566754083216095
course366567540833268107128214068540832661
of221568540833757
metastatic228668540835792114147174197229251267298
melanoma.259868540835893108141179217275308321
Int29336854083155374
J3021685408324
Cancer.305968540834073111143177198208
2014;134(1):102-113.328168540833468100131143173203239258290304316346377410431461489519531
doi:10.1002/ijc.28338.21406954083387692104134165178208240276309335351367399412448482516549583596
38.21407053085357085
Zaretsky22357054083376888121142168196228
JM,24747054083247789
Garcia-Diaz25737054083437494124137168189234248279307
A,289070540834153
Shin29547054083326882118
DS,30837054083447587
et318170540833354
al.32457054083324657
Mutations331370540835490111142162176213249274
associated3598705408331568111814916319321407154083215492
with22437154083506586123
acquired23777154083316299135149169202240
resistance2628715408321547993118140172208239272
to291171540832157
PD-1297971540833578101130
blockade31207154083395490122151183221254
in338571540831551
melanoma.344771540835791106137173210267298310
N3768715408345
Engl214072540833370108123
J2274725408324
Med.231072540835489127140
2016;375(9):819-829.24627254083346798129140174206238255286304315349380410432468501534544
doi:10.1056/NEJMoa1604958.30187254083387590101130161173203234267301325370403429483520553582612647682715748782794
39.21407353085367185
Jin22447354083243977
W.234073540835767
Role24267354083367490125
of257073540833756
JAK/STAT3264573540832464100128161196233262297
Signaling29617354083334886124157172187225264
in324473540831452
the33157354083226095
Regulation342973540833570110147163195217232270308
of375673540833857
Metastasis,214074540835490112145171194227254268295308
the24617454083226095
Transition25707454083325083121147162184200238276
of286074540833756
Cancer293074540834073111143177198
Stem31427454083325387145
Cells,33017454083397389104130143
and345874540833169109
Chemoresistance3580745408340781131712092140755408321558296122146178216249282
of243975540833756
Cancer251175540834073111143177198
by272575540833970
Epithelial–Mesenchymal28127554083327187109147182198213245260297353388415450488520558589647680695
Transition.35237554083335083121147162185200238276290
Cells.21407654083407489104130144
2020;9(1):217.229976540833469101136148184203235249261296328357363
doi:10.3390/cells9010217.26787654083387691103133165177213246279315339368402417432458493529560592625656686692
40.3940553085377693
Karachaliou4057554083367194128162202236252268308348
N,44295540834660
Gonzalez-Cao45125540834586126157192209245276299344378418
M,49545540835671
Crespo5049554083416399127168208
G,52815540834560
et53655540833558
al.5447554083335063
Interferon55345540831655394065408322567899134156194233
gamma,41946540833871129188221234
an44496540833270
important45406540831574113153175200233271293
marker48546540835891112143178200
of50756540833757
response5153654083215582122161200227262
to54366540832260
immune5516654083157439407540835998138174
check-point41367540833272109143174196237278294334356
blockade4514754083405796131162197238274
in48107540831555
non-small48867540833979119143171231264281297
cell5205754083326784100
lung5326754083165594135
cancer548375408332661063940854083316586
and40468540833169109
melanoma41748540835792108140178217275307
patients.4501854083387193108143181203230244
Ther47658540833271106128
Adv49128540834179112
Med50448540835489129
Oncol.51928540834786118155171184
2018;10.53958540833468100131143174205218
doi:10.1177/1758834017749748.3940954083387692104134165178208236265300320353382415449485519554590622651686716749782813849862
41.39401053085366981
Kim403710540833551109
TK,41621054083336984
Herbst426310540834479100140166190
RS,44691054083356982
Chen456710540834078113151
L.473510540833145
Defining47961054083468199116153169206245
and505810540833270109
Understanding518310540834482121156177204227260298337352390429
Adaptive394011540834077108146168182214247
Resistance41981154083356995109134156188225256288
in449811540831451
Cancer456111540833971108139171192
Immunotherapy.476411540831571127164200238259295329350382419450459
Trends52351154083324881118156181
Immunol.54281154083147112716339401254083387692105
2018;39(8):624-631.406012540833468100131143178211231264282294330363395418455489520529
doi:10.1016/j.it.2018.05.001.46041254083397792104134166178209240272303328345358373396409445479511542556591625637672708740749
42.39401353085367086
Koyama404513540833572104137194227
S,429113540833245
Akbay435513540834171112145175
EA,45491354083337690
Li465813540833147
YY,47231354083367483
et482413540833457
al.49001354083314760
Adaptive497913540834179111150172188220255
resistance5253135408320548196122145178216248282
to555413540832158
therapeutic39401454083226095116149188224261284299331
PD-1428914540833580104135
blockade44421454083395593125155189228263
is472314540831441
associated47821454083315884123155171203224258298
with50981454083506688126
upregulation52421454083377798132172209225257279294332370
of394015540833757
alternative40171554083324870104125164197219234267301
immune433915540831472130168206242
check-points.460115540833170105138168188228267283321343371384
Nat50061554083457799
Commun.512615540834077135193231269283
2016;7.542915540833569101132144177184
doi:10.1038/ncomms10501.39401654083387692104134165178208240273307333369401438496554581611642676710742752
43.39401753085367186
Taube40461754083336198137173
JM,42391754083247992
Young435117540833569107145184
GD,455517540834490101
McMiller467617540835487142157173188222244
TL,49401754083326579
et503917540833356
al.51151754083314760
Differential5195175408345608099134155189227248264296311
expression55261754083346639401854083386093120146160198236
of418818540833756
immune-regulatory425718540831471128165203237260282315354392407438460496517551
genes482018540833873110145171
associated50041854083315784121154168200221255294
with53101854083506588125
PD-L1544818540833579102135164
display39401954083385379118134166197
in415019540831452
melanoma:421519540835792108140178216274306319
Implications454719540831472111127142174207228243281320346
for49061954083185677
PD-1499619540833580104135
pathway51441954083387193131181214245
blockade.5402195408338549212515518839402054083387385
Clin40402054083395570107
Cancer416220540834073111143177198
Res.43742054083357097111
2015;21(17):3969-3976.449920540833469100130141176208223254284303315350384419453476509542575607620
doi:10.1158/10780432.CCR-15-0244.51342054083387691103133165177208236266300325358390422456394021540833470103136148188226261283314344366403436468505518
44.39402253085367691
Vétizou40532254083367092108138176215
M,428922540835569
Pitt4379225408336517499
JM,44992254083248094
Daillère46142254083467995110126161183218
R,485322540833650
et492422540833558
al.50032254083324861
Anticancer508522540834281103118151185224256291313
immunotherapy54192254083147313217139402354083387698136171192225264296
by425323540833970
CTLA-4434023540834076109152174210
blockade45682354083385492125155189228263
relies4848235408321557085120147
on501223540833776
the51052354083226095
gut52182354083387598
microbiota.53332354083587310512616320321825639402454083225468
Science40282454083326580114153185218
(80-42672454083185287111
).439824540831930
2015;350(6264):1079-1084.444824540833468100130141176209243262296329363399416428458490522556579610641677713726
doi:10.1126/science.aad1329.51942454083387692104134165178208236266300325349381396394025540833472104138150184216255287317350384395
45.39402653085367185
Sivan40382654083324779111149
A,419926540834154
Corrales42662654083397697118151166200227
L,450526540833145
Hubert456226540834481119155175200
N,477426540834457
et484326540833456
al.49112654083324760
Commensal498326540834076134191225263289321336
Bifidobacterium53322654083355067841221601992312633940275408321547590127183
promotes41362754083385995152190211244270
antitumor44182754083326990105126164220258279
immunity470927540831471128165202216238271
and499227540833269107
facilitates5111275408318518297112126148180201234260
anti-PD-53832754083326990105126162206229
-L139402854083215484
efficacy.4043285408334527088120153185219229
Science.42912854083336580115153185219231
2015;350(6264):1084-1089.454128540833468100130141176209243263296329363399417429458490525562585615647682717728
doi:10.1126/52882854083387692104134165178208236266299325
science.aac4255.39402954083265873108146178212224258290323355388423455467
46.39403053085367389
Shaikh404230540833270102117147186
FY,42413054083326977
Gills4331305408343597489115
JJ,44583054083244860
Sears45313054083326799120147
CL.46913054083407184
Impact478830540831573111144176200
of500130540833756
the50703054083226094
microbiome517730540835772104125162202217255313348
on553830540833775
check-point394031540833169104137167187227266282319341
inhibitor43003154083145290105144160182219241
treatment45603154083214377109131189224262283
in486231540831553
patients49333154083397294109144182203231
with51833154083506688127
non-small532831540833876115137164222254269284
cell3940325408331658196
lung40493254083155290129
cancer419132540833265103135168190
and439432540833270109
melanoma.451632540835792108140178216275307320
EBioMedicine.48503254083326883121176211251266298313351386398
2019;48:642647.526132540833569101131144178214227262298331394033540833471103109
doi:10.1016/j.ebiom.2019.08.076.40643354083387692104134165178209240272303328344357392431447485543556592626658688699734770783818851883896
47.39403453085367180
McQuade403534540835487137175208248284
JL,43333454083245771
Ologun441934540834764102143181220
GO,465334540834492104
Arora477234540834062100123156
R,494334540833550
Wargo500734540835890112150189
JA.52113454083246480
Gut530534540834483106
Microbiome54253454083557110412616439403554083395593152188
Modulation414235540835594134172188221243259298337
Via44933554083355385
Fecal459335540833266100133149
Microbiota475735540835470103124162202219257280313
Transplant50843554083335184123150190206239278300
to539835540832259
Augment547135540834179119394036540835793132154
Immunotherapy410836540831573132170208247270309344366400439471
in459436540831453
Patients46613654083356890106141180202231
with49063654083506790128
Melanoma504936540835490106139177216275308
or537236540833759
Other544536540834771110146168
Cancers.394037540834176116150185208237252
Curr421537540834179102125
Oncol436337540834889123162179
Rep.456537540833673114128
2020;22(7).471637540833571106142156193230249285306319
doi:10.1007/s11912020-00913-y.50573754083398096110142175189221255293327349375407436468502534394038540833468103127165202238270301324356367
48.39403953085367490
Yang404539540833565103142
M,420139540835568
Wang428439540835889127166
Y,446539540833543
Yuan452339540833570103141
M,467839540835568
et476139540833456
al.48323954083324760
Antibiotic490739540834179101116155170208230246278
administration519939540833271129144182197223246268301323338376414
shortly394040540832663101122146161192
before41444054083397392129150184
or434040540833758
after44104054083325075108128
immunotherapy455140540831471128165202240261299333354386425456
initiation5019405408314526688103134156171208246
is527740540831440
correlated53294054083316788110143158190211244283
with39404154083516689127
poor408241540833877116137
prognosis42344154083396098137175213240255281
in453041540831452
solid4597415408326648095134
cancer474641540833164102134168189
patients:49504154083397293109143181203231243
An520841540834179
up-to-date530241540833776100122159182223255277310
systematic39404254083265884107140197229250265296
review42494254083205485101135185
and444642540833269108
meta-analysis.456642540835791113145167199236268283314341355381394
Int49724254083155273
Immunopharmacol.505842540831471128165202240279317349369427459490526542555
2020;88.394043540833468101135148183219232
doi:10.1016/j.intimp.2020.106876.41874354083397792104134166178209240272303328345358373411433448506545558594628661695707738769805841874906919
49.39404453085367285
Gopalakrishnan404444540834482122155170203233255271297335373405443
V,450644540833645
Spencer457044540833371107145177211232
CN,48224454083398497
Nezi493944540834479109124
L,508344540833145
et514744540833456
al.52234454083324760
Gut530244540834482105
microbiome54264454083577210412616339404554083395594153189
modulates415045540835898138176192225247282309
response44804554083215684123163202229265
to476645540832260
anti-PD-148474554083327193109131169215239271
immunotherapy513945540831573132171210249271310346368401441473
in394046540831553
melanoma400846540835893108140178217275307
patients.43314654083397293109143181203231244
Science45914654083326580115153185218
(80-48254654083195288111
).495246540831930
2018;359(6371):97-103.499746540833569100131144179212244263296330362395409421456489508538570603615
doi:10.1126/science.aan4236.39404754083387692104134165178208236266300325349381396431469501535547581613651687719754788802
50.39404853085367287
Chaput404148540834078110149187210
N,426448540834558
Lepage433548540833165105138177212
P,456048540833540
Coutzac461348540834077115137168202234
C,486048540834053
et492648540833456
al.49964854083314760
Baseline50694854083356895130145160198233
gut53154854083387699
microbiota54274854083577210412616339404954083405696119153
predicts41154954083406298139155189214243
clinical43804954083324864103119153187203
response46054954083215785126166206234270
and489749540833372113
colitis50324954083327087103127143170
in522449540831554
metastatic530049540835996119154181206240263279312
melanoma394050540835894111144183222282315
patients42765054083397396112147186208237
treated45345054083224479112134169210
with47655054083516891130
ipilimumab.4916505408315557187103162200259293333346
Ann528350540834281120
Oncol.542450540834888121159175189
2017;28(6):1368-1379.394051540833468100129139174208227260278290320350384420442473503535569580
doi:10.1093/annonc/mdx108.45355154083387692104134165178208240275308332362400438477515547575631670701733764800813
51.39405253085367082
Matson404152540835487109136175213
V,427352540833645
Fessler43365254083336794120135170191
J,454652540832537
Bao460152540833669107
R,472752540833549
et479552540833456
al.48705254083324760
The494952540833372107
commensal507552540833168126184219257284317332
microbiome54265254083577310512616339405354083395594154190
is415153540831542
associated42145354083326087126160176208231265306
with45415354083526891130
anti-PD-146925354083337294110132170216241272
efficacy4986535408334537190123156189224
in523153540831554
metastatic530653540835894117151178202236258274307
melanoma394054540835893108141179217276308
patients.42695454083397294109144182204232245
Science45355454083326580115153186219
(80-47755454083195288112
).490754540831930
2018;359(6371):104-108.495754540833569101132144179213245264298332364396411423453484521544575607642656
doi:10.1126/science.aao3290.39405554083387692104134165178208236266300325349381396431469501535547581613651685717752787800
52.39405653085357085
Tanoue40385654083325997134172206
T,425756540833240
Morita431056540835391112128150182
S,450456540833245
Plichta4561565408335496495133154186
DR,47605654083448094
et486656540833355
al.49345654083314659
A5005565408340
defined50585654083377189105142177216
commensal528656540833167124181216253279312327
consortium394057540833167105132169191215231268325
elicits4278575408334496496111134161
CD8445257540834085119
T4585575408332
cells4630575408331648095121
and476457540833169108
anti-cancer48855754083316990106128161194231263297318
immunity.521657540831572129166204219241275285
Nature.55145754083447639405854083215980113125
2019;565(7741):600-605.40785854083346799129141176210243261295329359389403415450485520544581616649661
doi:10.1038/s41586-019-0878-z.47525854083387591103132163176206237270304329353388418448481516540576608637661697732765798820847860
53.39405953085367186
Hegazy404059540834479119151181215
AN,42695954083418699
West438359540835790117140
NR,45385954083448094
Stubbington46475954083325391130170186224263285322361
MJT,502259540835580115124
et516059540833456
al.52315954083324760
Circulating53065954083395576107145160192214229267306
and394060540833270109
Tissue-Resident40696054083335076102140175198235270297312351385424445
CD4+453460540834086122166
T4720605408333
Cells47736054083407489104130
With49246054083577396134
Reactivity507860540833671103135159174207223245279
to537760540832259
Intestinal5456605408315537510813539406154083223876109125
Microbiota408661540835571103125163203219258280314
Are44216154083416398
Abundant453961540834282121160199232271293
in485361540831553
Healthy492761540834581113129152191222
Individuals51706154083155393109142158198236269284311
and550261540833271111
Function394062540833370108141165181220259
Is422062540831541
Altered42826254083415780114136170211
During451462540834584106122160200
Inflammation.4735625408315537188121179238271293309347386400
Gastroenterology.51566254083447710412815018722426228431834037839443339406354083387080
2017;153(5):1320-1337.e16.403263540833468100129139169198231249282301312342372404438462492522555587593627657688701
doi:10.1053/j.gastro.2017.07.047.47466354083377591103132163176206238272304328345357396428454477499536548584618649678684719752758793829860866
54.39406453085367388
Frankel40426454083325285123153187203
AE,42586454083417487
Coughlin435964540834077115154192207222260
LA,46326454083327589
Kim473464540833552109
J,485764540832436
et490664540833456
al.49766454083314760
Metagenomic504964540835490112145184219257295353368400
Shotgun546364540833270108130394065540833876113
Sequencing406665540833368107145179217249264302341
and442065540833270109
Unbiased454165540834482121136168195230269
Metabolomic482365540835489111144183222238276334349381
Profiling52176554083355593110127142157195234
Identify546465540831453881263940665408321365589
Specific404166540833270105137152169186217
Human427166540834380137169206
Gut449066540834380102
Microbiota460566540835368100120157196211248270302
and491966540833269107
Metabolites503966540835388110142180218234248270303330
Associated5381665408340689413116317820939406754083225595
with40526754083516789127
Immune419767540831472130168206241
Check-point445567540834078113146176196236275290328350
Therapy482267540833372107128161200232
Efficacy5071675408333516886118151183217
in530567540831553
Melanoma537567540835590106138176214394068540835790
Patients.40506854083356789104139177199226240
Neoplasia430768540834580118158174206233248280
(United460768540831963100115138172211
States).48396854083325386108142168186196
2017;19(10):848-855.505668540833468100129139169199219250282300312347383419442478512544556
doi:10.1016/j.neo.2017.08.004.39406954083387692104134165178208240272303328344357396431470482518552584613619655690703739775811823
55.39407053085377389
Ralli40537054083367187103119
M,419670540835671
Botticelli42917054083367699125141175210227243259
A,457470540834257
Visconti46557054083375482116154195217234
IC,49137054083155872
et500870540833559
al.50917054083334963
Immunotherapy517870540831575135175214255278318354377411394071540834073
in404271540831555
the412671540832363100
Treatment42557154083345389123146207244284307
of459271540833859
Metastatic468071540835693117152180205240264280314
Melanoma:502371540835694111145185226287321335
Current538771540834179102126162202225
Knowledge394072540833473111161176210249287322
and427472540833169107
Future43937254083326890127148181
Directions.45867254083456081114146170185222260285299
J4897725408324
Immunol493372540831571128165203240256
Res.52017254083356995108
2020;2020.53227254083346799133145179213245278291
doi:10.1155/2020/9235638.39407354083387692104134165178208236266299322357391424458483517550585618652686720734
56.39407453085367288
Kitano40487454083355174107145183
S,425074540833346
Nakayama431574540834577107141172205263295
T,462974540833342
Yamashita469074540833665123155182220235257290
M.499974540835569
Biomarkers50877454083365189147180201231266287314
for54217454083185677
Immune551874540831472394075540835998137173
Check-point413575540834180116150182203244284301340362
Inhibitors45197554083155494110150167190228251279
in482075540831554
Melanoma.489675540835592108142181221281314328
Front52467554083335492132155
Oncol.542275540834889122160177190
2018;8(July):1-8.394076540833468100131143178197222260276307326338367386422435
doi:10.3389/fonc.2018.00270.43917654083387691104133165177213246280314338357395433465479515549580612625660696729762795808